http://bit.ly/2D2yYSK.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970182 | PMC |
| http://dx.doi.org/10.1183/23120541.00311-2019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Costs of Oral Corticosteroid Use in Patients with Severe Asthma With/Without Chronic Rhinosinusitis with Nasal Polyps: Data from the Italian SANI Registry.
Adv Ther
January 2025
Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Clinical and Research Hospital, Via Alessandro Manzoni 56, 20089, Rozzano, MI, Italy.
Introduction: The burden of severe asthma on patients, especially on those with concomitant chronic rhinosinusitis with nasal polyps (CRSwNP), is substantial. Treatment intensification with oral corticosteroids is a common strategy for managing severe asthma exacerbations; however, prolonged exposure to systemic corticosteroids is associated with multisystem toxicity. This study aimed to quantify the association between oral corticosteroid use and annual asthma-related costs in patients with severe asthma with or without CRSwNP.
View Article and Find Full Text PDFCyclosporin A as an adjunct may enhance the therapeutic effect of interferon alpha-2a in patients with refractory Behcet's uveitis: a retrospective cohort study.
Ther Adv Chronic Dis
December 2024
The First Affiliated Hospital of Chongqing Medical University, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China.
Background: The application of biologic agents has benefited patients with Behcet's uveitis (BU) who do not respond to conventional treatment regimens. However, there is currently no consensus on the optimal treatment regimen of interferon alpha-2a (IFN-α2a) for refractory BU.
Objectives: To evaluate treatment outcomes and safety of IFN-α2a in a large series of refractory BU patients and to explore whether nonbiologic immunomodulatory agents (cyclosporin A) other than corticosteroids should be concomitantly used.
Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: long-term observation of the MARS study.
Mod Rheumatol
November 2024
Global Medical Affairs, GSK, London, UK.
Article Synopsis
- The MARS study aimed to collect long-term safety and effectiveness data for mepolizumab treatment in patients with eosinophilic granulomatosis with polyangiitis in Japan.
- In the study, conducted over 192 weeks, about 58% of patients experienced adverse events, but none were linked directly to mepolizumab. There were notable improvements in patient symptoms and a decrease in the need for oral glucocorticoids.
- The findings support that mepolizumab is well tolerated and effective for managing this condition, demonstrating an increase in symptom-free patients and decreased steroid dependency.
Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in UC: Analyses of the ELEVATE UC Clinical Programme.
J Crohns Colitis
September 2024
Department of Internal Medicine, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany.
Article Synopsis
- Etrasimod is an oral medication targeting specific receptors to treat moderately to severely active ulcerative colitis, with safety and efficacy analyzed based on prior corticosteroid use in the ELEVATE UC clinical trials.
- In the trials, a greater percentage of patients on etrasimod achieved clinical remission compared to those on placebo, both for those currently using corticosteroids and those not, particularly noting a significant rate of corticosteroid-free remission in the corticosteroid subgroup at Week 52.
- Safety profiles were similar across subgroups, with no increase in infection rates observed in patients using corticosteroids, demonstrating that etrasimod is effective and safe for UC patients regardless of prior corticosteroid
Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial.
Am J Ophthalmol
November 2024
From the F.I. Proctor Foundation, University of California (N.R.A., J.A.G., T.D., A.C., T.C.P., J.G.S.), San Francisco, California, USA; Department of Ophthalmology, University of California (N.R.A., J.A.G., T.D., T.C.P., J.G.S.), San Francisco, California, USA.
Purpose: To compare the effectiveness of methotrexate (MTX) and mycophenolate mofetil (MMF) in achieving corticosteroid-sparing control of uveitis in patients with Vogt-Koyanagi-Harada (VKH) disease.
Methods: A subanalysis of patients with VKH from the First-line Antimetabolites as Steroid-sparing Treatment Uveitis Trial, a randomized, observer-masked, comparative effectiveness trial, with comparisons by treatment (MTX vs MMF) and disease stage (acute vs chronic). Individuals with noninfectious uveitis were placed on a standardized corticosteroid taper and block randomized 1:1 to either 25 mg weekly oral MTX or 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!